Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN)

Sanctuary Advisors LLC purchased a new stake in shares of Lantern Pharma Inc. (NASDAQ:LTRN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $32,000. Sanctuary Advisors LLC owned 0.09% of Lantern Pharma as of its most recent SEC filing.

Separately, Westside Investment Management Inc. increased its stake in Lantern Pharma by 166.5% during the third quarter. Westside Investment Management Inc. now owns 30,650 shares of the company’s stock valued at $112,000 after acquiring an additional 19,150 shares during the period. Institutional investors own 28.62% of the company’s stock.

Lantern Pharma Price Performance

Shares of LTRN opened at $3.89 on Friday. Lantern Pharma Inc. has a 12-month low of $2.79 and a 12-month high of $11.99. The firm has a market capitalization of $41.95 million, a price-to-earnings ratio of -2.19 and a beta of 1.64. The stock’s 50-day moving average price is $4.23 and its 200 day moving average price is $3.82.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.